Ignite Creation Date:
2024-05-05 @ 5:34 PM
Last Modification Date:
2024-10-26 @ 9:33 AM
Study NCT ID:
NCT00485966
Status:
WITHDRAWN
Last Update Posted:
2008-11-05
First Post:
2007-06-11
Brief Title:
Study Evaluating Effects of CX-3543 in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia
Sponsor:
Cylene Pharmaceuticals
Organization:
Cylene Pharmaceuticals
Study Overview
Official Title:
A Phase 2 Multi-Center Open Label Study Evaluating Clinical Efficacy Safety and Pharmacodynamic Effects of Quarfloxacin CX-3543 in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia B-CLL
Status:
WITHDRAWN
Status Verified Date:
2008-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
This study was withdrawn prior to patient enrollment
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a Phase 2 open-label multicenter efficacy safety and pharmacodynamic study of CX-3543 in patients with relapsed or refractory B-cell chronic lymphocytic leukemia CLL
Detailed Description:
The purpose of this trial is to evaluate the response rate safety pharmacodynamic effects and duration of response of CX-3543 in patients with relapsed or refractory B-cell CLL
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None